Sensei Biotherapeutics Business Summary

Sensei Biotherapeutics, Inc. (SNSE) is a clinical-stage biotechnology company that generates value through the discovery and development of next-generation oncology therapeutics, operating primarily as a pre-revenue research and development entity. Following its February 2026 acquisition of Faeth Therapeutics and a concurrent $200 million private placement, the company has pivoted its primary focus to PIKTOR, a multi-node inhibitor of the PI3K/AKT/mTOR pathway currently in Phase 2 trials for endometrial cancer and Phase 1b for HR+/HER2- breast cancer. This lead asset is complemented by the company’s legacy Tumor Microenvironment Activated Biologics (TMAb) platform, which includes solnerstotug (SNS-101), a conditionally active VISTA-targeting antibody undergoing Phase 1/2 evaluation. Sensei competes in the high-stakes immuno-oncology and kinase inhibitor markets against firms such as BioNTech, Replimune, and Gritstone bio, positioning itself as a specialist in overcoming the efficacy-tolerability trade-offs of traditional single-node inhibitors through its dual PI3K-alpha and mTORC1/2 targeting strategy. Leadership is currently spearheaded by Christopher W. Gerry, who serves as President, Principal Executive Officer, and General Counsel, bringing extensive legal and strategic experience from his tenure at AVROBIO and Cooley LLP. The executive team was significantly bolstered in February 2026 by the appointment of Anand Parikh as Chief Operating Officer; Parikh, a co-founder of Faeth Therapeutics and former executive at Virta Health, joins a scientific lineage that includes Faeth’s world-renowned founders such as PI3K discoverer Lewis Cantley and Pulitzer Prize-winning physician Siddhartha Mukherjee. Financial oversight is managed by Josiah Craver, Senior Vice President of Finance, while the board is chaired by Bob Holmen. The company is backed by a high-pedigree investor syndicate including RA Capital Management, Balyasny Asset Management, Cormorant Asset Management, and Vivo Capital, providing a robust capital runway to reach key clinical readouts through late 2026.